Arcutis Biotherapeutics holder plans sale of 4730 shares

Arcutis Biotherapeutics shareholder Howard Welgus plans to sell up to 4730 shares of common stock through Merrill Lynch on NASDAQ, with an approximate sale date of 07/15/2026 and an aggregate market value of 127284.3.

Rhea-AI Filing Summary

Arcutis Biotherapeutics shareholder Howard Welgus plans to sell up to 4730 shares of common stock through Merrill Lynch on NASDAQ, with an approximate sale date of 07/15/2026 and an aggregate market value of 127284.3. The shares come from restricted stock vesting and stock option exercises totaling 634, 822, 1019 and 2255 shares. The notice also lists prior sales of 7144, 4096 and 635 shares on 05/01/2026, 06/15/2026 and 06/17/2026, respectively.

Key Figures

Planned shares to be sold: 4730 shares Aggregate market value of planned sale: 127284.3 Shares outstanding: 125083374 shares +5 more

8 metrics

Planned shares to be sold 4730 shares Common stock planned for sale through Merrill Lynch on NASDAQ

Aggregate market value of planned sale 127284.3 Value associated with 4730 common shares to be sold

Shares outstanding 125083374 shares Outstanding common shares referenced alongside the planned sale

Approximate sale date 07/15/2026 Planned sale date for 4730 common shares

Restricted stock vesting amount 634 shares Common shares from Restricted Stock Vesting on 06/04/2026

Stock option exercise amounts 822, 1019, 2255 shares Common shares from Stock Option Exercise events in 2019, 2023 and 2024

Sale on 05/01/2026 7144 shares for 164219.71 Arcutis Biotherapeutics common stock sold during past 3 months

Sales on 06/15/2026 and 06/17/2026 4096 shares for 99980.49; 635 shares for 16300.45 Additional past 3‑month common stock sales

Key Terms

Restricted Stock Vesting, Stock Option Exercise, Securities Sold During The Past 3 Months, Securities Information

4 terms

Restricted Stock Vesting financial

"Common | 06/04/2026 | Restricted Stock Vesting | Arcutis Biotherapeutics"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Stock Option Exercise financial

"Common | 11/20/2019 | Stock Option Exercise | Arcutis Biotherapeutics"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Securities Sold During The Past 3 Months regulatory

"144: Securities Sold During The Past 3 Months"

Securities Information regulatory

"144: Securities Information Common | Merrill Lynch 8890 Lyra Drive"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Arcutis Biotherapeutics (ARQT) shares are planned for sale?

The seller plans to sell up to 4730 Arcutis Biotherapeutics common shares, with an aggregate market value of 127284.3. These shares are part of the company’s total outstanding common stock of 125083374 shares listed in the notice.

When is the planned sale date for the ARQT shares?

The approximate planned sale date for the 4730 Arcutis Biotherapeutics shares is 07/15/2026. This date appears in the securities information section, alongside details of the broker, market value and NASDAQ listing for the common stock.

Which broker and market are involved in the planned ARQT share sale?

The planned sale of 4730 Arcutis Biotherapeutics common shares will be handled through Merrill Lynch, at 8890 Lyra Drive, Columbus, Ohio. The securities are indicated for trading on the NASDAQ market according to the notice details.

What transactions generated the ARQT shares to be sold?

The 4730 shares to be sold arise from a Restricted Stock Vesting of 634 shares on 06/04/2026 and three Stock Option Exercise events for 822, 1019 and 2255 shares dated 11/20/2019, 05/31/2023 and 06/14/2024, respectively.

What ARQT shares has the seller disposed of in the past 3 months?

The notice lists past 3‑month sales of 7144 shares for proceeds of 164219.71 on 05/01/2026, 4096 shares for 99980.49 on 06/15/2026 and 635 shares for 16300.45 on 06/17/2026, all in Arcutis Biotherapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/15/2026 - 04:01 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns Gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Howard Welgus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 8890 Lyra Drive 5th Floor Columbus OH 43240	4730	127284.3	125083374	07/15/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2026	Restricted Stock Vesting	Arcutis Biotherapeutics			634	06/04/2026	NA
Common	11/20/2019	Stock Option Exercise	Arcutis Biotherapeutics			822	07/15/2026	Cash
Common	05/31/2023	Stock Option Exercise	Arcutis Biotherapeutics			1019	07/15/2026	Cash
Common	06/14/2024	Stock Option Exercise	Arcutis Biotherapeutics			2255	07/15/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	05/01/2026	7144	164219.71
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	06/15/2026	4096	99980.49
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	06/17/2026	635	16300.45

144: Remarks and Signature

Remarks
Date of Notice	07/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Howard Welgus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)